Cambridge Pre-U Syllabus - Cambridge International Examinations
Cambridge Pre-U Syllabus - Cambridge International Examinations
Cambridge Pre-U Syllabus - Cambridge International Examinations
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
32<br />
3.5 The immune system<br />
Content<br />
Structure, function and physiology of the mammalian immune system<br />
Monoclonal antibodies<br />
<strong>Cambridge</strong> <strong>Pre</strong>-U Draft<br />
Learning outcomes<br />
Candidates should be able to:<br />
a) contrast the specific and non-specific immune systems<br />
b) outline the role of B-cells, plasma cells, memory cells, helper-T cells and cytotoxic-T cells in giving<br />
specific immune primary and secondary responses<br />
c) discuss the structure and action of antibodies (including variable and non-variable regions of the<br />
monomeric immunoglobin IgG, but not including the range of types and functions of immunoglobins)<br />
d) distinguish between active and passive immunity, as well as natural and artificial immunity, limited to<br />
specific examples including tetanus, TB, polio and measles<br />
e) describe the cause and means of transmission of malaria and discuss its global impact and why it is<br />
difficult to control<br />
f) explain the term autoimmune disease with reference to type 1 diabetes and myasthenia gravis<br />
g) outline the ABO blood group system and discuss its implications in transfusion and hyperacute rejection<br />
of transplanted organs<br />
h) outline the principles involved in histocompatibility and acute transplant rejection (details of the MHC<br />
system are not required)<br />
i) outline the production of monoclonal antibodies and explain why it is necessary to use hybridoma cells<br />
for this purpose<br />
j) discuss and evaluate the use of monoclonal antibodies compared to conventional methods for diagnosis<br />
and treatment including pregnancy testing, diagnosis of HIV/AIDS and radioimmunotherapy of cancer<br />
Practical learning outcomes<br />
X ref Section 3.1, Practical Learning outcome (i)